Vaccine comprising
The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.
1. A multivalent Streptococcus pneumoniae immunogenic composition comprising components including saccharide conjugate components, wherein the saccharide conjugate components consist of conjugates of capsular saccharides of 16 different serotypes of Streptococcus pneumoniae wherein the different Streptococcus pneumoniae serotypes are selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, wherein the capsular saccharides are separately conjugated to 2 or more different carrier proteins,
wherein the serotype 22F capsular saccharide has an average saccharide size of between 50 and 800 kDa,
wherein the serotype 19F capsular saccharide is conjugated to diphtheria toxoid,
wherein the serotype 19F capsular saccharide is the only capsular saccharide conjugated to the diphtheria toxoid,
wherein the capsular saccharides from half of the 16 different Streptococcus pneumoniae serotypes are conjugated to protein D from Haemophilus influenzae , and wherein the immunogenic composition comprises an adjuvant, wherein the adjuvant is selected from the group consisting of a metal salt, an oil in water emulsion, a Toll like receptor agonist, saponin, and a combination thereof.
2. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 1 , wherein the capsular saccharides of the Streptococcus pneumoniae serotypes are conjugated to 3 different carrier proteins.
3. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 1 , wherein the capsular saccharides of the Streptococcus pneumoniae serotypes are conjugated to 5 different carrier proteins.
4. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 1 further comprising one or more unconjugated or conjugated Streptococcus pneumoniae proteins.
5. A method of inducing an immune response in a human against disease caused by Streptococcus pneumoniae infection comprising administering an immunoprotective dose of the multivalent Streptococcus pneumoniae immunogenic composition of claim 1 .
6. A method of inducing an immune response in a human against disease caused by Streptococcus pneumoniae infection comprising administering an immunoprotective dose of the multivalent Streptococcus pneumoniae immunogenic composition of claim 2 .
7. A method of inducing an immune response in a human against disease caused by Streptococcus pneumoniae infection comprising administering an immunoprotective dose of the multivalent Streptococcus pneumoniae immunogenic composition of claim 3 .
8. A method of inducing an immune response in a human against disease caused by Streptococcus pneumoniae infection comprising administering an immunoprotective dose of the multivalent Streptococcus pneumoniae immunogenic composition of claim 4 .
9. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 1 , wherein the capsular saccharides of the Streptococcus pneumoniae serotypes are conjugated to 4 different carrier proteins.
10. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 1 wherein the serotype 19A capsular saccharide has an average saccharide size of between 50 and 800 kDa.
11. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 1 wherein the serotype 18C capsular saccharide has an average saccharide size of between 70 and 300 kDa.
12. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 1 wherein the capsular saccharides are sized by microfluidisation.
13. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 1 wherein the serotype 18C capsular saccharide is sized by microfluidisation.
14. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 1 wherein the adjuvant is selected from a metal salt and a Toll like receptor agonist and wherein the metal salt is an aluminum salt.
15. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 1 wherein the adjuvant is selected from an aluminum salt and a Toll like receptor agonist and the aluminum salt is an aluminum phosphate salt and the Toll like receptor is a Toll like receptor 4 agonist.
16. The multivalent Streptococcus pneumoniae immunogenic composition according to claim 15 wherein the Toll like receptor 4 agonist is 3D-MPL.